vs
Astrana Health, Inc.（ASTH）与科慕（CC）财务数据对比。点击上方公司名可切换其他公司
科慕的季度营收约是Astrana Health, Inc.的1.4倍（$1.3B vs $950.5M），Astrana Health, Inc.净利率更高（0.7% vs -3.5%，领先4.2%），Astrana Health, Inc.同比增速更快（42.9% vs -2.1%），科慕自由现金流更多（$92.0M vs $-6.0M），过去两年Astrana Health, Inc.的营收复合增速更高（53.3% vs -1.2%）
Astrana Health是一家总部位于美国的价值导向型医疗服务提供商，主要服务全美符合联邦医保资格的老年群体，提供上门初级护理、慢性病管理及护理协调服务，致力于提升患者健康水平、降低不必要的医疗支出。
科慕公司是一家美国化工企业，2015年7月从杜邦分拆成立，总部位于美国特拉华州威尔明顿。公司主营产品包括具备不粘特性的知名品牌特氟龙（聚四氟乙烯PTFE）、二氧化钛以及制冷剂气体，在特种化工领域拥有深厚的技术积累。
ASTH vs CC — 直观对比
营收规模更大
CC
是对方的1.4倍
$950.5M
营收增速更快
ASTH
高出45.0%
-2.1%
净利率更高
ASTH
高出4.2%
-3.5%
自由现金流更多
CC
多$98.0M
$-6.0M
两年增速更快
ASTH
近两年复合增速
-1.2%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $950.5M | $1.3B |
| 净利润 | $6.6M | $-47.0M |
| 毛利率 | — | 11.7% |
| 营业利润率 | 1.9% | — |
| 净利率 | 0.7% | -3.5% |
| 营收同比 | 42.9% | -2.1% |
| 净利润同比 | 184.4% | -261.5% |
| 每股收益（稀释后） | $0.12 | $-0.32 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ASTHCC
| Q4 25 | $950.5M | $1.3B | ||
| Q3 25 | $956.0M | $1.5B | ||
| Q2 25 | $654.8M | $1.6B | ||
| Q1 25 | $620.4M | $1.4B | ||
| Q4 24 | $665.2M | $1.4B | ||
| Q3 24 | $478.7M | $1.5B | ||
| Q2 24 | $486.3M | $1.6B | ||
| Q1 24 | $404.4M | $1.4B |
净利润ASTHCC
| Q4 25 | $6.6M | $-47.0M | ||
| Q3 25 | $373.0K | $46.0M | ||
| Q2 25 | $9.4M | $-380.0M | ||
| Q1 25 | $6.7M | $-5.0M | ||
| Q4 24 | $-7.8M | $-13.0M | ||
| Q3 24 | $16.1M | $-32.0M | ||
| Q2 24 | $19.2M | $60.0M | ||
| Q1 24 | $14.8M | $54.0M |
毛利率ASTHCC
| Q4 25 | — | 11.7% | ||
| Q3 25 | — | 15.6% | ||
| Q2 25 | — | 17.2% | ||
| Q1 25 | — | 17.3% | ||
| Q4 24 | — | 19.4% | ||
| Q3 24 | — | 19.0% | ||
| Q2 24 | — | 19.8% | ||
| Q1 24 | — | 20.9% |
营业利润率ASTHCC
| Q4 25 | 1.9% | — | ||
| Q3 25 | 2.0% | 2.5% | ||
| Q2 25 | 3.1% | -15.4% | ||
| Q1 25 | 3.3% | — | ||
| Q4 24 | 0.1% | -0.1% | ||
| Q3 24 | 5.9% | -2.1% | ||
| Q2 24 | 6.2% | 4.4% | ||
| Q1 24 | 7.5% | 5.1% |
净利率ASTHCC
| Q4 25 | 0.7% | -3.5% | ||
| Q3 25 | 0.0% | 3.1% | ||
| Q2 25 | 1.4% | -23.5% | ||
| Q1 25 | 1.1% | -0.4% | ||
| Q4 24 | -1.2% | -1.0% | ||
| Q3 24 | 3.4% | -2.1% | ||
| Q2 24 | 3.9% | 3.9% | ||
| Q1 24 | 3.7% | 4.0% |
每股收益（稀释后）ASTHCC
| Q4 25 | $0.12 | $-0.32 | ||
| Q3 25 | $0.01 | $0.31 | ||
| Q2 25 | $0.19 | $-2.53 | ||
| Q1 25 | $0.14 | $-0.03 | ||
| Q4 24 | $-0.14 | $-0.07 | ||
| Q3 24 | $0.33 | $-0.22 | ||
| Q2 24 | $0.40 | $0.39 | ||
| Q1 24 | $0.31 | $0.36 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $429.5M | $670.0M |
| 总债务越低越好 | — | $4.1B |
| 股东权益账面价值 | $779.3M | $250.0M |
| 总资产 | $2.2B | $7.4B |
| 负债/权益比越低杠杆越低 | — | 16.40× |
8季度趋势，按日历期对齐
现金及短期投资ASTHCC
| Q4 25 | $429.5M | $670.0M | ||
| Q3 25 | $463.4M | $613.0M | ||
| Q2 25 | $342.1M | $502.0M | ||
| Q1 25 | $260.9M | $464.0M | ||
| Q4 24 | $290.8M | $713.0M | ||
| Q3 24 | $350.3M | $596.0M | ||
| Q2 24 | $327.7M | $604.0M | ||
| Q1 24 | $337.3M | $746.0M |
总债务ASTHCC
| Q4 25 | — | $4.1B | ||
| Q3 25 | — | $4.1B | ||
| Q2 25 | — | $4.1B | ||
| Q1 25 | — | $4.1B | ||
| Q4 24 | — | $4.1B | ||
| Q3 24 | — | $4.0B | ||
| Q2 24 | — | $4.0B | ||
| Q1 24 | — | $4.0B |
股东权益ASTHCC
| Q4 25 | $779.3M | $250.0M | ||
| Q3 25 | $775.5M | $274.0M | ||
| Q2 25 | $765.5M | $228.0M | ||
| Q1 25 | $745.4M | $566.0M | ||
| Q4 24 | $712.7M | $571.0M | ||
| Q3 24 | $704.6M | $643.0M | ||
| Q2 24 | $678.9M | $714.0M | ||
| Q1 24 | $653.5M | $753.0M |
总资产ASTHCC
| Q4 25 | $2.2B | $7.4B | ||
| Q3 25 | $2.2B | $7.5B | ||
| Q2 25 | $1.4B | $7.5B | ||
| Q1 25 | $1.3B | $7.4B | ||
| Q4 24 | $1.4B | $7.5B | ||
| Q3 24 | $1.3B | $7.5B | ||
| Q2 24 | $1.3B | $7.2B | ||
| Q1 24 | $1.2B | $8.0B |
负债/权益比ASTHCC
| Q4 25 | — | 16.40× | ||
| Q3 25 | — | 14.96× | ||
| Q2 25 | — | 17.99× | ||
| Q1 25 | — | 7.18× | ||
| Q4 24 | — | 7.11× | ||
| Q3 24 | — | 6.20× | ||
| Q2 24 | — | 5.53× | ||
| Q1 24 | — | 5.27× |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $-2.9M | $137.0M |
| 自由现金流经营现金流 - 资本支出 | $-6.0M | $92.0M |
| 自由现金流率自由现金流/营收 | -0.6% | 6.9% |
| 资本支出强度资本支出/营收 | 0.3% | 3.4% |
| 现金转化率经营现金流/净利润 | -0.44× | — |
| 过去12个月自由现金流最近4个季度 | $104.5M | $51.0M |
8季度趋势，按日历期对齐
经营现金流ASTHCC
| Q4 25 | $-2.9M | $137.0M | ||
| Q3 25 | $10.0M | $146.0M | ||
| Q2 25 | $90.9M | $93.0M | ||
| Q1 25 | $16.6M | $-112.0M | ||
| Q4 24 | $-10.9M | $138.0M | ||
| Q3 24 | $34.0M | $139.0M | ||
| Q2 24 | $23.2M | $-620.0M | ||
| Q1 24 | $6.0M | $-290.0M |
自由现金流ASTHCC
| Q4 25 | $-6.0M | $92.0M | ||
| Q3 25 | $7.4M | $105.0M | ||
| Q2 25 | $89.5M | $50.0M | ||
| Q1 25 | $13.6M | $-196.0M | ||
| Q4 24 | $-13.5M | $29.0M | ||
| Q3 24 | $31.7M | $63.0M | ||
| Q2 24 | $20.4M | $-693.0M | ||
| Q1 24 | $5.6M | $-392.0M |
自由现金流率ASTHCC
| Q4 25 | -0.6% | 6.9% | ||
| Q3 25 | 0.8% | 7.0% | ||
| Q2 25 | 13.7% | 3.1% | ||
| Q1 25 | 2.2% | -14.3% | ||
| Q4 24 | -2.0% | 2.1% | ||
| Q3 24 | 6.6% | 4.2% | ||
| Q2 24 | 4.2% | -44.6% | ||
| Q1 24 | 1.4% | -28.8% |
资本支出强度ASTHCC
| Q4 25 | 0.3% | 3.4% | ||
| Q3 25 | 0.3% | 2.7% | ||
| Q2 25 | 0.2% | 2.7% | ||
| Q1 25 | 0.5% | 6.1% | ||
| Q4 24 | 0.4% | 8.0% | ||
| Q3 24 | 0.5% | 5.0% | ||
| Q2 24 | 0.6% | 4.7% | ||
| Q1 24 | 0.1% | 7.5% |
现金转化率ASTHCC
| Q4 25 | -0.44× | — | ||
| Q3 25 | 26.69× | 3.17× | ||
| Q2 25 | 9.65× | — | ||
| Q1 25 | 2.48× | — | ||
| Q4 24 | — | — | ||
| Q3 24 | 2.11× | — | ||
| Q2 24 | 1.21× | -10.33× | ||
| Q1 24 | 0.40× | -5.37× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ASTH
| Medicare | $542.4M | 57% |
| Commercial | $99.1M | 10% |
| Care Delivery | $92.1M | 10% |
| Care Enablement | $78.9M | 8% |
| Other Third Parties | $58.0M | 6% |
| Health Care Patient Service | $39.8M | 4% |
| Health Care Other | $25.5M | 3% |
| Other | $12.1M | 1% |
| Management Service | $10.3M | 1% |
CC
| Titanium Technologies | $563.0M | 42% |
| Thermal And Specialized Solutions | $443.0M | 33% |
| Advanced Performance Materials | $312.0M | 23% |
| Other Non-Reportable Segment | $12.0M | 1% |
